ClinicalTrials.gg
CompletedNCT00509236Updated May 12, 2017Results posted

Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)

A Phase 3 interventional study of Sitagliptin and Glipizide in Diabetes Mellitus, Type 2 and End-Stage Kidney Disease, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2017-05-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
90th of 197
129 · median 102
Started
2007
with 16 others
Phase 3
74 of 198
none open now
Registered
30th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 90th largest by enrollment of the 197 interventional ones that give a count, is one of 17 that started in 2007, is one of 74 in phase 3, and was the 30th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of the study is to compare sitagliptin and glipizide in lowering blood sugar in participants with type-2 diabetes mellitus (T2DM) and end-stage renal disease on dialysis who do not have adequate glycemic control.

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • End-Stage Kidney Disease
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has T2DM.
  • Participant is on dialysis on day of signing .
  • Participant is unlikely to conceive or uses acceptable methods of : hormonal contraceptive, intrauterine device (IUD), diaphragm with spermicide, contraceptive sponge, condom, or vasectomy.
  • Participant has ≥7% and ≤9% measured at or within 2 weeks prior to Visit 4/Week -2.
  • Participant is ≥85% compliant with study medication during the single-blind placebo run-in (as determined by tablet/capsule count) and compliant with diet, exercise and other run-in treatments during the run-in period.

Exclusion criteria

Exclusion Criteria:

  • Participant has a history of type 1 diabetes mellitus or a history of ketoacidosis.
  • Participant is losing weight in a weight loss program and is not in the maintenance phase (defined as \<2 kg weight loss in 2 months), or intends to be involved in weight loss intervention outside that prescribed by the study.
  • Participant has a hematological disorder (e.g., aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia).
  • Participant has cirrhosis or active liver disease.
  • Participant has been on dialysis for \< 6 months.
  • Participant has been diagnosed with a significant cardiovascular disorder and has new or worsening signs or symptoms of congestive heart failure within 3 months of signing .
  • Participant has severe active peripheral vascular disease.
  • Participant has a history of ≤ 5 years prior to signing informed consent, or > 5 years without documentation of remission/cure.
  • Participant is under treatment for hyperthyroidism.
  • Participant has a or to glipizide.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
129 participants (actual)

Study arms

  • Experimental
    Sitagliptin 25 mg

    Drug: Sitagliptin

  • Active comparator
    Glipizide 2.5 mg - 20 mg

    Drug: Glipizide

Interventions

  • 25 mg (one 25-mg tablet) once daily

    Also known as: MK-0431

  • 2.5 mg (1/2 of a 5-mg tablet) once daily, up to 10 mg twice daily (four 5-mg tablets), for a maximum of 20 mg

    Also known as: Glucotrol

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c After Sitagliptin Treatment

    Change from baseline in mean hemoglobin A1c after treatment with sitagliptin for 54 weeks. Hemoglobin A1c is the percent of hemoglobin that is glycated. Results for the glipizide arm are not reported in this table because the primary outcome measure is for the sitagliptin arm only.

    Time frame: Baseline / Week 54

  2. Number of Participants With Clinical Adverse Events

    Reported experiences assessed by investigators as adverse events, excluding data after initiation of glycemic rescue therapy.

    Time frame: 54 Week Treatment Period + 28 days

Secondary outcomes

  1. Number of Participants With Symptomatic Hypoglycemic Adverse Events

    A symptomatic hypoglycemic adverse event is an episode with clinical symptoms attributed to hypoglycemia, without regard to fingerstick glucose level.

    Time frame: 54 Week Treatment Period + 28 days

  2. Change From Baseline in Fasting Plasma Glucose (FPG)

    Change from baseline in mean Fasting Plasma Glucose after treatment with sitagliptin versus glipizide for 54 weeks.

    Time frame: Baseline / Week 54

  3. Change From Baseline in Hemoglobin A1c for Sitagliptin Versus Glipizide Treatment

    Change from baseline in least square means hemoglobin A1c after treatment with sitagliptin versus glipizide for 54 weeks. Hemoglobin A1c is the percent of hemoglobin that is glycated.

    Time frame: Baseline / Week 54

07

Results

Posted May 3, 2012

Participant flow

Participant flow — Overall Study
MilestoneSitagliptin 25 mgGlipizide 2.5 mg - 20 mg
Started6465
Completed4745
Not completed1720
Withdrew: Adverse event79
Withdrew: Withdrawal by subject510
Withdrew: Protocol violation30
Withdrew: Excluded medication11
Withdrew: Scheduled kidney transplant10

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1c After Sitagliptin Treatment

Change from baseline in mean hemoglobin A1c after treatment with sitagliptin for 54 weeks. Hemoglobin A1c is the percent of hemoglobin that is glycated. Results for the glipizide arm are not reported in this table because the primary outcome measure is for the sitagliptin arm only.

Time frame:
Baseline / Week 54
Reported as:
Mean · Percent hemoglobin A1c
Change From Baseline in Hemoglobin A1c After Sitagliptin Treatment
Percent hemoglobin A1cSitagliptin 25 mg
Baseline7.89 ± 0.74
Week 547.15 ± 0.98
Change from Baseline at Week 54-0.74 ± 0.95
Statistical analysis
  • Sitagliptin 25 mg · ANCOVA · p = <0.001
SecondaryNumber of Participants With Symptomatic Hypoglycemic Adverse Events

A symptomatic hypoglycemic adverse event is an episode with clinical symptoms attributed to hypoglycemia, without regard to fingerstick glucose level.

Time frame:
54 Week Treatment Period + 28 days
Reported as:
Number · Participants
Number of Participants With Symptomatic Hypoglycemic Adverse Events
ParticipantsSitagliptin 25 mgGlipizide 2.5 mg - 20 mg
Number of Participants With Symptomatic Hypoglycemic Adverse Events47
Statistical analysis
  • Sitagliptin 25 mg vs Glipizide 2.5 mg - 20 mg · Miettinen & Nurminen · p = 0.336 (Miettinen \& Nurminen method stratified by prior diabetes pharmacotherapy (not on oral antihyperglycemic agent, or on oral antihyperglycemic agent).) · Difference in % affected: -4.8 · 95% CI -15.7 to 5.6
PrimaryNumber of Participants With Clinical Adverse Events

Reported experiences assessed by investigators as adverse events, excluding data after initiation of glycemic rescue therapy.

Time frame:
54 Week Treatment Period + 28 days
Reported as:
Number · Participants
Number of Participants With Clinical Adverse Events
ParticipantsSitagliptin 25 mgGlipizide 2.5 mg - 20 mg
Number of Participants With Clinical Adverse Events5352
Statistical analysis
  • Sitagliptin 25 mg vs Glipizide 2.5 mg - 20 mg · Difference in % affected: 2.8 · 95% CI -10.9 to 16.5
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG)

Change from baseline in mean Fasting Plasma Glucose after treatment with sitagliptin versus glipizide for 54 weeks.

Time frame:
Baseline / Week 54
Reported as:
Mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG)
mg/dLSitagliptin 25 mgGlipizide 2.5 mg - 20 mg
Baseline160.3 ± 48.5167.0 ± 56.2
Week 54135.8 ± 40.4134.0 ± 58.2
Change from Baseline to Week 54-24.5 ± 47.5-33.0 ± 55.9
Statistical analysis
  • Sitagliptin 25 mg · ANCOVA · p = <0.001 · Change from baseline in ls mean: -26.6 · 95% CI -38.0 to -15.3
  • Glipizide 2.5 mg - 20 mg · ANCOVA · p = <0.001 · Change from baseline in ls mean: -31.2 · 95% CI -42.6 to -19.9
  • Sitagliptin 25 mg vs Glipizide 2.5 mg - 20 mg · Difference in ls means: 4.6 · 95% CI -11.5 to 20.7
SecondaryChange From Baseline in Hemoglobin A1c for Sitagliptin Versus Glipizide Treatment

Change from baseline in least square means hemoglobin A1c after treatment with sitagliptin versus glipizide for 54 weeks. Hemoglobin A1c is the percent of hemoglobin that is glycated.

Time frame:
Baseline / Week 54
Reported as:
Least squares mean · Percent hemoglobin A1c
Change From Baseline in Hemoglobin A1c for Sitagliptin Versus Glipizide Treatment
Percent hemoglobin A1cSitagliptin 25 mgGlipizide 2.5 mg - 20 mg
Change From Baseline in Hemoglobin A1c for Sitagliptin Versus Glipizide Treatment-0.72 (-0.95 to -0.48)-0.87 (-1.11 to -0.63)
Statistical analysis
  • Sitagliptin 25 mg vs Glipizide 2.5 mg - 20 mg · ANCOVA · Difference in ls means: 0.15 · 95% CI -0.18 to 0.49

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin 25 mg—23/64 (35.9%)33/64 (51.6%)
Glipizide 2.5 mg - 20 mg—22/65 (33.8%)37/65 (56.9%)
Most frequent serious events
Showing 10 of 62
Most frequent serious events
EventSitagliptin 25 mgGlipizide 2.5 mg - 20 mg
Catheter site infectionInfections and infestations0/644/65
Device malfunctionGeneral disorders2/640/65
GastroenteritisInfections and infestations2/641/65
Septic shockInfections and infestations2/640/65
Urinary tract infectionInfections and infestations2/641/65
Subdural haematomaInjury, poisoning and procedural complications2/640/65
Acute pulmonary oedemaRespiratory, thoracic and mediastinal disorders2/640/65
Cardiac failure congestiveCardiac disorders1/642/65
PeritonitisGastrointestinal disorders0/642/65
Device related infectionInfections and infestations1/642/65
Most frequent other events
Showing 10 of 12
Most frequent other events
EventSitagliptin 25 mgGlipizide 2.5 mg - 20 mg
Blood glucose decreasedInvestigations11/6418/65
CoughRespiratory, thoracic and mediastinal disorders7/646/65
Upper respiratory tract infectionInfections and infestations3/647/65
HypoglycaemiaMetabolism and nutrition disorders4/647/65
HypertensionVascular disorders5/646/65
Urinary tract infectionInfections and infestations5/641/65
DiarrhoeaGastrointestinal disorders2/645/65
Oedema peripheralGeneral disorders1/645/65
Blood glucose increasedInvestigations4/645/65
VomitingGastrointestinal disorders4/642/65

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sitagliptin 25 mgGlipizide 2.5 mg - 20 mgTotal
Mean60.5 ± 9.158.5 ± 9.959.5 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)Sitagliptin 25 mgGlipizide 2.5 mg - 20 mgTotal
Female242852
Male403777
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Arjona Ferreira JC, Corry D, Mogensen CE, Sloan L, Xu L, Golm GT, Gonzalez EJ, Davies MJ, Kaufman KD, Goldstein BJ. Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial. Am J Kidney Dis. 2013 Apr;61(4):579-87. doi: 10.1053/j.ajkd.2012.11.043. Epub 2013 Jan 24. Erratum In: Am J Kidney Dis. 2013 Oct;62(4):847. PubMed 23352379 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2007 to primary completion in Mar 2011, 40 months.

Results were first posted in May 2012, 1 year 1 month after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 40 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2007
First posted
Jul 31, 2007
StartActual
Oct 19, 2007
Primary completionActual
Mar 14, 2011
CompletionActual
Mar 14, 2011
Results first posted
May 3, 2012
Last update
May 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00509236
Responsible party
Sponsor
First posted
Jul 31, 2007
Start date
Oct 19, 2007
Primary completion
Mar 14, 2011
Completion
Mar 14, 2011
Results posted
May 3, 2012
Last update
May 12, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion